NCT01152060

Brief Summary

Lamivudine treatment for HBV-DNA negative HBV-GN patients.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2010

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

June 28, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 29, 2010

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2010

Completed
Last Updated

June 29, 2010

Status Verified

May 1, 2010

Enrollment Period

10 months

First QC Date

June 28, 2010

Last Update Submit

June 28, 2010

Conditions

ProteinuriaHBVe-antigen

Keywords

remission of proteinuriaHBVe-antigen

Study Arms (2)

prednisone

prednisone and anti-virus

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

HBV-MN patients with heavy proteinuria in adults; HBsAg or HBeAg positive; HBV-DNA negative

You may qualify if:

  • Adult HBV-GN patients with biopsy-proven MN, heavy protinuria, HBsAg or HBeAg positive, HBV-DNA negative

You may not qualify if:

  • Primary MN patients, HBV-DNA positive

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • von Groote TC, Williams G, Au EH, Chen Y, Mathew AT, Hodson EM, Tunnicliffe DJ. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD004293. doi: 10.1002/14651858.CD004293.pub4.

    PMID: 34778952DERIVED

  • Xu G, Duang Z, Wu X, Zou H, Fang X, Tu W. Treatment of hepatitis B virus-associated membranous nephritis patients in Chinese: an open parallel controlled trial. Clin Chem Lab Med. 2011 Jun;49(6):1077-8. doi: 10.1515/CCLM.2011.168. Epub 2011 Mar 17. No abstract available.

    PMID: 21410411DERIVED

MeSH Terms

Conditions

Proteinuria

Condition Hierarchy (Ancestors)

Urination DisordersUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Gaosi XU, MD & PhD

    second affiliated hospital to nanchang university

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 28, 2010

First Posted

June 29, 2010

Study Start

January 1, 2010

Primary Completion

November 1, 2010

Study Completion

November 1, 2010

Last Updated

June 29, 2010

Record last verified: 2010-05